Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10722176		
Filing Date		2003-11-24		
First Named Inventor RANA		A, Taniq M.		
Art Unit		1635		
Examiner Name	Kimbi	erly Chong		
Attorney Docket Number		20336-00016(prev UMY-059)		

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Pate of cited Docu	entee or Applicant ment	Releva	s,Columns,Lines whe ant Passages or Rele as Appear	
	1									
If you wis	h to a	i dadditional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva	s,Columns,Lines whe ant Passages or Rele as Appear	
	1									
If you wish	h to a	dd additional U.S. Publi						d buttor		
	_		_	FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	Ts
	1									
If you wis	h to a	l dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add	
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country volume-issue number published.						Тв				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10722176		
iling Date		2003-11-24		
irst Named Inventor RANA		, Taniq M.		
Art Unit		1635		
xaminer Name	Kimbi	Comberly Chong		
Months Number		20336-00016(prev UMY-059)		

	1	CHIU, Y L., ALI, A., CHU, C.Y., CAO, H., & RANA, T.M., Visualizing a Correlation between siRNA Localization, Cellular Uptake, and RNAI in Living Cells, Chemistry and Biology, 11: 1165-1175, August 2004	
	2	INVITROGEN CORPORATION, Lipofectamine™ RNAMAX transfection guidelines, pp 1-4, Rev. 11 January 2006.	
	3	KANC, H. et al., Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides, Pharm Res. 2005 Dec; 22(12):2099-2106	
	4	LEE, J.H., et al., Quaternized Polyamidoamine Dendrimers as Novel Gene Delivery System: Relationship between Degree of Quaternization and their influences, Builetin of the Korean Chemical Scorety, 2003, 24(11) 1637-1640).	
	5	STEVENS, M.P., Polymer Chemistry. An Introduction, 3rd Ed., pp. 301-303, Oxford University Press, New York 1999	
	6	SVENSON, S., & TOMALIA, D.A., Dendrimers in biomedical applications—reflections on the field, Adv Drug Deliv Rev. 2005 Dec 14;57(15):2106-2129	
	7	TOMALIA, D.A., Birth of a New Macromolecular Architecture: Dendrimers as Quantized Building Blocks for Nanoscale Synthetic Organic Chemistry, Aldrichmica Acta, 37(2): 39-57, 2004.	
	8	ZHOU, J., et al., PAMAM dendmers for efficient siRNA delivery and potent gene silencing, Chem Commun (Camb). 2006 Jun 14 (22) 2362-4)	
If you wie	h to a	td additional non-patent literature document citation information please click the Add hutton Add	\neg

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER SIGNATURE

Examiner Signature Date Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

1 See Kind Codes of USPTO Patent Documents at www.uSPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. § Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10722176
Filing Date		2003-11-24
First Named Inventor RANA		A, Tariq M.
Art Unit		1635
Examiner Name Ki		orly Chong
Attorney Docket Number		20336-00016(prev UMY-059)

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.57(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Roger P. Zimmerman/	Date (YYYY-MM-DD)	2006-11-07
Name/Print	Roger P. Zimmerman	Registration Number	38.670

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral purpuses for which the information is used by the U.S. Patient and Trademan Colline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested region of the patient of the patient application of the patient application of the patient activities, which may result in farministion of proceedings or 4 anahoroment of the application of the patients of the pa

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.